Slide 1: Investor Presentation Q2 FY22
Investor Presentation Q2 FY22 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Biocon is a global biopharmaceutical company
Biocon is a global biopharmaceutical company that is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives. 3
Slide 4: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and • Focus on the kind of expertise to enhance access to innovation that adds the essential drugs for patients on condition of affordability to As a committed the lowest rung of the accessibility stakeholder of the economic l
Slide 5: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Enzymes Transforming into Building the Base Strategic Global Commercialized Poised for Company a Biopharma Business and Alliance with Mylan Biosimilars for Global Impact Company Experti
Slide 6: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs 7,360 Cr 12,000+ Revenue* Total Employees* 1,200+ 25+ Patents cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where our Among Top 10 Global products are Biotech Employers by available Science magazine *FY21
Slide 7: Business Segments
Business Segments 7
Slide 8: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring access Pushing scientific Expanding access Partnering to through quality, bounda
Slide 9: Generics: Investing into capacities and capabilities for the future growth
Generics: Investing into capacities and capabilities for the future growth Differentiated API business Growing Formulations Footprint Investments for future growth • 5 state-of-the-art facilities across Bangalore, • Oral solids (potent & non-potent), parenteral & • Expanding our R&D capabilities for
Slide 10: Generics: Q2 FY22
Generics: Q2 FY22 KEY HIGHLIGHTS Q2 FY22 Q2 FY21 - Pricing pressure in US - Slower ramp-up of demand for APIs Revenue ₹530Cr ₹604Cr Operational and supply chain challenges in the earlier part of the quarter 12% YoY decrease - Day 1 launch of Everolimus in the US - Statins held on to market share Pro
Slide 11: Novel Molecules: Pushing scientific boundaries to deliver impactful innovations
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress • Phase I multiple ascending dose studies in Type 1 DM patients ongoing in Germany; in Insulin Tregopil- a first-in-class oral, prandial partnership with US-based Juvenile Diabetes Res
Slide 12: Novels: Q2 FY22
Novels: Q2 FY22 KEY HIGHLIGHTS Equillium on track to initiate a Phase 3 pivotal study on Itolizumab in first-line acute GvHD* in Q4 CY21 Bicara# continues to make progress in dose finding part of the Phase 1 trial for its lead program, BCA101 *Graft-versus-host disease #In Q4FY21, Biocon ceded contr
Slide 13: Biosimilars: Fully integrated global player in an attractive market
Biosimilars: Fully integrated global player in an attractive market Product Status Therapeutic Areas Molecule US Dev. Markets: ex-US MoW5 Commercialized several biosimilars in Pegfilgrastim1 Europe, CANZ developed and emerging markets 1 Trastuzumab Europe, CANZ Oncology 1 Bevacizumab Europe, AU Robu
Slide 14: Entering adjacencies in communicable disease: infectious disease antibodies and vaccines
Entering adjacencies in communicable disease: infectious disease antibodies and vaccines Key Commercial Products Recent Collaborations 50,000+ lives impacted Continued portfolio expansion 14
Slide 15: Key terms of alliance with SILS
Key terms of alliance with SILS 1 2 3 Committed revenue Access to 100m doses of Commercialization rights stream and related vaccines annually for 15 of the SILS portfolio for margins from years global markets H2 FY23 ~15% stake in BBL at a post-money valuation of ~$4.9bn Alliance will develop antibo
Slide 16: Biosimilars: Q2 FY22
Biosimilars: Q2 FY22 KEY HIGHLIGHTS Q2 FY22 Q2 FY21 Strategic alliance with Serum Institute Life Sciences (SILS) to foray into Revenue vaccines with access to 100m doses/year for 15 years ₹743Cr ₹676Cr Partnered with Adagio Therapeutics to manufacture & commercialize 10% YoY increase a novel antibod
Slide 17: Research Services (Syngene)
Research Services (Syngene) Offering integrated research, development and manufacturing services for both small and large molecules, antibody-drug conjugates & oligonucleotides backed by best-in-class bioinformatic services World-class R&D and manufacturing infrastructure spread over 2 million squar
Slide 18: Research Services: Q2 FY22
Research Services: Q2 FY22 KEY HIGHLIGHTS Q2 FY22 Q2 FY21 Strong performance across all divisions Revenue In Discovery Services, positive demand for newer services like Protein ₹610Cr ₹520Cr Degradation Technology (PROTACS) & peptide synthesis 17% YoY increase Uptick in Development Services as clien
Slide 19: Financial Highlights
Financial Highlights 19
Slide 20: Annual Financial Highlights
Annual Financial Highlights FY21 FY20 Biosimilars +21% | Research Services Revenue +13% ₹7,360Cr ₹6,462Cr +9% | Generics +6% Core EBITDA1 +15% ₹2,430Cr ₹2,108Cr Forex loss of ₹9Cr in FY21 vs ₹65Cr of Forex gain in FY20 % margin 33% 33% Gross R&D spends at ₹627Cr in FY21 EBITDA +8% ₹1,907Cr ₹1,765Cr
Slide 21: Financial Highlights: Q2 FY22
Financial Highlights: Q2 FY22 Q2 FY22 Q2 FY21 Biosimilars +10% | Research Services Revenue +10% ₹1,945Cr ₹1,765Cr +17% | Generics (12)% Core EBITDA* +8% ₹609Cr ₹564Cr Forex Gain of ₹20Cr vs ₹18Cr of loss in Q2 FY21 % margin 33% 32% Gross R&D spend at ₹165Cr – Similar to EBITDA +35% ₹551Cr ₹407Cr Q2
Slide 22: Thank You
Thank You INVESTOR RELATIONS CONTACT: Aishwarya Sitharam, Biocon Limited Tel: +91 93236 48143 Email: aishwarya.sitharam@biocon.com Nikunj Mall, Biocon Biologics Limited Tel : +91 998 777 4078 Email: nikunj.mall@biocon.com 22